Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
The American Journal of Managed Care
|
March 13, 2008
Can managed care organizations partner with manufacturers for comparative effectiveness research?
Bryan R Luce, L Clark Paramore, Bhash Parasuraman, et al.
JCO Oncology Practice
|
May 21, 2026
Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024
Julia A Rucker, Molly T Beinfeld, Daniel Enright, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
December 1, 2005
Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting
Kevin B Weiss, L Clark Paramore, Bengt Liljas, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
April 3, 2003
Budesonide Turbuhaler delivered once daily improves health-related quality of life and maintains improvements with a stepped-down dose in adults with mild to moderate asthma
Thomas B Casale, Harold S Nelson, James Kemp, et al.
Allergy and Asthma Proceedings
|
June 5, 2003
Budesonide turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma
Charles Banov, William C Howland, William R Lumry, et al.
Journal of Medical Economics
|
October 26, 2024
Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma
Ling Cai, Jack Roos, Paulo A P Miranda, et al.
Leukemia & Lymphoma
|
May 24, 2023
Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia
Jeff P Sharman, Paulo Miranda, Jack Roos, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|
April 1, 2006
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study
Kevin Weiss, Martin Buxton, Fredrik L Andersson, et al.
The Journal of Allergy and Clinical Immunology
|
December 6, 2003
Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma
Sean D Sullivan, Martin Buxton, L Fredrik Andersson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 24, 2005
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report
Scott Ramsey, Richard Willke, Andrew Briggs, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
The American Journal of Managed Care
|
March 13, 2008
Can managed care organizations partner with manufacturers for comparative effectiveness research?
Bryan R Luce, L Clark Paramore, Bhash Parasuraman, et al.
JCO Oncology Practice
|
May 21, 2026
Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024
Julia A Rucker, Molly T Beinfeld, Daniel Enright, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
December 1, 2005
Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting
Kevin B Weiss, L Clark Paramore, Bengt Liljas, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
April 3, 2003
Budesonide Turbuhaler delivered once daily improves health-related quality of life and maintains improvements with a stepped-down dose in adults with mild to moderate asthma
Thomas B Casale, Harold S Nelson, James Kemp, et al.
Allergy and Asthma Proceedings
|
June 5, 2003
Budesonide turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma
Charles Banov, William C Howland, William R Lumry, et al.
Journal of Medical Economics
|
October 26, 2024
Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma
Ling Cai, Jack Roos, Paulo A P Miranda, et al.
Leukemia & Lymphoma
|
May 24, 2023
Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia
Jeff P Sharman, Paulo Miranda, Jack Roos, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|
April 1, 2006
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study
Kevin Weiss, Martin Buxton, Fredrik L Andersson, et al.
The Journal of Allergy and Clinical Immunology
|
December 6, 2003
Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma
Sean D Sullivan, Martin Buxton, L Fredrik Andersson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 24, 2005
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report
Scott Ramsey, Richard Willke, Andrew Briggs, et al.
Page
of 3